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systematic review of qualitative research
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Abstract
Objective To synthesise the findings from individual qualitative studies
on patients’ understanding and experiences of hypertension and drug
taking; to investigate whether views differ internationally by culture or
ethnic group and whether the research could inform interventions to
improve adherence.
Design Systematic review and narrative synthesis of qualitative research
using the 2006 UK Economic and Social Research Council research
methods programme guidance.
Data sourcesMedline, Embase, the British Nursing Index, Social Policy
and Practice, and PsycInfo from inception to October 2011.
Study selection Qualitative interviews or focus groups among people
with uncomplicated hypertension (studies principally in people with
diabetes, established cardiovascular disease, or pregnancy related
hypertension were excluded).
Results 59 papers reporting on 53 qualitative studies were included in
the synthesis. These studies came from 16 countries (United States,
United Kingdom, Brazil, Sweden, Canada, New Zealand, Denmark,
Finland, Ghana, Iran, Israel, Netherlands, South Korea, Spain, Tanzania,
and Thailand). A large proportion of participants thought hypertension
was principally caused by stress and produced symptoms, particularly
headache, dizziness, and sweating. Participants widely intentionally
reduced or stopped treatment without consulting their doctor. Participants
commonly perceived that their blood pressure improved when symptoms
abated or when they were not stressed, and that treatment was not
needed at these times. Participants disliked treatment and its side effects
and feared addiction. These findings were consistent across countries
and ethnic groups. Participants also reported various external factors
that prevented adherence, including being unable to find time to take
the drugs or to see the doctor; having insufficient money to pay for
treatment; the cost of appointments and healthy food; a lack of health
insurance; and forgetfulness.
Conclusions Non-adherence to hypertension treatment often resulted
from patients’ understanding of the causes and effects of hypertension;
particularly relying on the presence of stress or symptoms to determine
if blood pressure was raised. These beliefs were remarkably similar
across ethnic and geographical groups; calls for culturally specific
education for individual ethnic groups may therefore not be justified. To
improve adherence, clinicians and educational interventions must better
understand and engage with patients’ ideas about causality, experiences
of symptoms, and concerns about drug side effects.
Introduction
Hypertension is a major health problem in both developed and
developing countries and is estimated to cause more than 13%
of deaths annually.1Despite national and international guidelines
and initiatives for hypertension, population based studies have
found that around two thirds of people with hypertension are
either untreated or inadequately controlled, including a
substantial number who remain undiagnosed.2-4
Among those with a diagnosis of hypertension, theWorld Health
Organization has stated that low adherence to treatment is a key
factor impeding good control and has called for research into
adherence promoting interventions.5 Estimates of the rate of
poor adherence or non-adherence to treatment range from
30-50%.6The causes of poor adherence are complex and include
complicated drug regimens, the costs of drugs, older age, poor
social support, cognitive problems, and depression.7
In 2005 a study reviewed the qualitative research on drug taking
in a wide range of medical conditions and found that patients
often actively decided not to take drugs (intentional
non-adherence) rather than unintentionally omitting them.8 To
date, several patient educational interventions aimed at
promoting drug adherence in hypertension have been tested in
randomised controlled trials, but most simply informed patients
about the importance of adherence and were ineffective.9
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Extra material supplied by the author (see http://www.bmj.com/content/344/bmj.e3953?tab=related#webextra)
Search terms
No commercial reuse: See rights and reprints http://www.bmj.com/permissions Subscribe: http://www.bmj.com/subscribe
BMJ 2012;344:e3953 doi: 10.1136/bmj.e3953 (Published 9 July 2012) Page 1 of 16
Research
RESEARCH
A better understanding of patients’ perspectives, through
qualitative research, is therefore critical to provide an
explanation of the low rates of treatment, adherence, and control
and why educational interventions have so far failed, and to
inform the development of evidence based interventions to
improve management. Indeed, authors of studies of lay
epidemiology suggest that clinicians’ failure to recognise how
people understand disease causation and risk is one of the key
obstacles to the success of public health programmes.10-12
We carried out a systematic review and narrative synthesis of
qualitative studies on hypertension. Specifically, we examined
lay understandings about the causes of hypertension and
perspectives on drug taking.We also investigated how patients’
perspectives varied among different cultures and ethnic groups.
Methods
We searched electronic databases (Medline, Embase, the British
Nursing Index, Social Policy and Practice, and PsycInfo) from
inception until October 2011 and hand searched reference lists
of relevant papers. The search strategy combined established
methodological terms for qualitative research,13 with specific
terms for hypertension (see supplementary appendix 1).
Study selection
We included reports of face to face qualitative interviews and
focus groups published in peer reviewed journals looking at
patient perspectives on hypertension and drug taking; telephone
interviews and quantitative questionnaire analyses were
excluded. We included studies of people with uncomplicated
hypertension and excluded those principally (over 50%) of
people with existing cardiovascular disease or diabetes or who
were pregnant. Studies were included regardless of quality. One
reviewer (IJM) carried out the search and did an initial screen
of titles. Clearly irrelevant titles were excluded at this stage.
The remaining abstracts were independently considered for
inclusion by two reviewers (IJM and CMcK). Disagreements
were resolved by discussion. There was no language limitation
for inclusion, and translations were obtained for non-English
language papers.
Data synthesis and analysis
We carried out a narrative synthesis following the steps
recommended by theUKEconomic and Social ResearchCouncil
(ESRC) research methods programme guidance.14 This was
developed to encourage systematic and reproducible approaches
to narrative synthesis and promotes transparent reporting and
the assessment of the robustness of the results. The guidance
provides a toolbox of different methods for reviewers. We used
textual summary, tabulation, and thematic analysis to synthesise
the results.
Developing a theoretical model
The narrative synthesis guidance recommends developing a
hypothesis before data are collected.14 We hypothesised that
patients’ understanding and experiences of hypertension might
contribute to low rates of drug adherence and blood pressure
control.
Developing a preliminary synthesis and
exploring relations in the data
IJM used a standard template to extract a textual summary of
the populations, research question, and results of the included
studies; a sample of these was checked by CMcK. Relations in
the data were explored through thematic analysis. IJM and
CMcK independently extracted and organised emerging themes
using the “one sheet of paper” method,15 using the textual
summaries and the full text of papers when needed. A final list
of themes and the relations between them was agreed by
discussion and consensus. The full text papers were then coded
according to the presence or absence of themes. We tabulated
these codes by country to examine similarities and variation
across cultures.
Qualitative research does not permit statistical inferences: the
occurrence of a theme in more than one paper does not imply
that it is important or common in the population studied. It may,
however, provide a greater degree of certainty that the theme
is valid, even if in a few people, and therefore we have reported
the number of studies where a particular theme was found.
Assessing the robustness of the synthesis
We assessed the quality of the included papers using the
checklist by Dixon-Woods and colleagues (box). We used
specific criteria for each area to give a score out of 11; one
reviewer (IJM) assessed the quality of each paper. The use of
quality assessment when reviewing qualitative research has
been debated owing to the lack of agreement among researchers
about what criteria should be used, the multitude of possible
qualitative methods, and the role of subjective judgment in
analysis.16We therefore did not exclude papers with low quality
scores but used the scores to provide one indicator of the
robustness of the synthesis.
We then carried out two sensitivity analyses by reanalysing the
data after removing groups of studies thought to be possible
sources of bias. Firstly, we examined whether study quality
affected the conclusions by assessing the effect of removing
lower quality studies (scoring <9 out of 11) from the synthesis.
Secondly, to find if the large number of studies in ethnic
minority groups had led to unrepresentative conclusions, we
carried out a sensitivity analysis only looking at studies that
were not in ethnic minority groups.
Results
Overall, 59 papers reporting 53 qualitative studies met the
inclusion criteria (figure⇓ and table 1⇓). The studies were from
the United States (n=20), the United Kingdom (n=8), Brazil
(n=7), Sweden (n=3), Canada (n=2), the Netherlands (n=2),
New Zealand (n=2), Denmark (n=1), Finland (n=1), Ghana
(n=1), Iran (n=1), Israel (n=1), South Korea (n=1), Spain (n=1),
Tanzania (n=1), and Thailand (n=1). Forty studies used one to
one qualitative interviews, 11 used focus groups, and two used
a mixture of these methods. Twenty four of the 53 studies
included people only from ethnic minority groups. Areas
covered by study interviews included patients’ understanding
of the causes, effects, exacerbating factors, and consequences
of hypertension; attitudes towards drugs; and the perceived
influences of stress, diet, and racism.
Narrative synthesis
Causes of hypertension and the role of stress
The main causes of hypertension reported by participants were
stress, food, being overweight, family history, and alcohol (table
2⇓). Participants widely and strongly connected stress and
worries with hypertension: as a cause, an exacerbating factor,
and a consequence. A participant from a Dutch study seemed
to regard worry and blood pressure as synonymous23:
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Prompts for appraising qualitative research17
• Are the research questions clear?
• Are the research questions suited to qualitative inquiry?
• Are the following clearly described?
Sampling
Data collection
Analysis
• Are the following appropriate to the research question?
Sampling
Data collection
Analysis
• Are the claims made supported by sufficient evidence?
• Are the data, interpretations, and conclusions clearly integrated?
• Does the paper make a useful contribution?
It is the burden of my family. BP [blood pressure] is
a sort of . . . eh. Actually it doesn’t make a difference
how you call it: BP or worrying too much; it seems
to be the same thing
Stress from work, unemployment, finances, and family matters
were often mentioned as impediments to blood pressure control,
both directly and indirectly. Most participants reported that
stress led directly to increased blood pressure; but leading a
stressful life also caused difficulties in finding time to take
drugs, eat well, and attend clinic appointments.
Participants from 10 studies (Brazil, Iran, Sweden, United States,
and United Kingdom) described reducing or avoiding stress as
a consequence of their diagnosis, such as by relaxing, trying to
avoid arguments, and changing jobs.18 32 40 46 52 54 56-58 64 68
In three studies (Ghana and United States) a difficult life with
previous long term stresses was thought to be responsible for
hypertension.24 26 69 African-Americans participants in three US
studies and Black Caribbean participants in a UK study thought
that the stress of experiencing racism was responsible for their
high blood pressure.24-26 42 52
A significant stressful event in the past was thought to be
responsible for later hypertension by a few participants in four
studies (Ghana, Tanzania, United Kingdom, and United
States),24 42 69 70 as illustrated by a participant in the UK study:42
I was going through a lot of issues at work and I was
going through a lot of issues around race and
victimisation I was under extreme stress. So, I went
to my doctor and that’s when I was diagnosed with
high blood pressure
In seven studies (Canada, Netherlands, Thailand, United States,
and United Kingdom) hypertension was seen by some
participants as a temporary or curable condition that would not
require long term treatment.22 23 28 52 58 60 62
In five studies (Tanzania, United Kingdom, and United States),
some participants perceived hypertension to be a distinct
condition from high blood pressure,24 40 52 56 70 highlighted by a
participant in a US study 40:
My blood just boils, and you don’t know what’s
making it happen. You can’t help it. I can’t control it,
I’m the kind of person who just can’t keep my mouth
shut for nothing. That pertension can hit you at any
time. It’s higher and stronger than with pressure. If
you have pressure your blood is up, but not as high
as with pertension
Most participants understood that hypertension caused serious
complications, such as stroke (18 studies: Brazil, Sweden, South
Korea, Thailand, United Kingdom, United States), death (13
studies: Brazil, Canada, Denmark, Netherlands, Sweden, United
Kingdom, and United States), and heart disease (14 studies:
Brazil, Sweden, United Kingdom, and United States). Less
widely reported complications included kidney disease (three
studies: Brazil, United Kingdom, and United States), paralysis
(three studies: Canada and United States), suicide (one study,
Brazil), and thinning of the blood (one study, United States).
Awareness of possible complications was often a source of fear,
as illustrated by a participant in the study from Tanzania70:
I am afraid because I have seen a friend of mine die
suddenly. She was overweight and we were living
with her in the same house. She woke up in the
morning with no problems, ready to leave for work;
we talked until the last minute. Suddenly, she fell and
died on the spot
Participants in five studies (South Korea, Sweden, United
Kingdom, andUnited States) described that taking drugs reduced
anxiety or worries.20 48 51 52 58 This was often thought to be a
direct physiological action of drugs20 51 52 but in some cases
resulted from feeling protected from the complications of
hypertension.48 58However, participants in two studies (Sweden
and United States)51 52 negatively perceived drugs to function
as sedatives, as illustrated by a participant in the Swedish study51:
Well, that depends basically—no one kind of
medication—some doctors give us like the—oh,
sedatives out there to make you relax and go to sleep
that you can become addicted to. But other than that,
I don’t think it’s much of a dandy, but you have to
watch it once you get that sedative type
Symptoms and their meaning
Participants commonly (13 countries, 27 studies) reported
symptoms that they connected with hypertension, particularly
headache and dizziness (table 3⇓). Participants in 16 of the
studies reported that hypertension caused them no symptoms.
In 11 studies (Brazil, Denmark, Netherlands, New Zealand,
Spain, Thailand, United Kingdom, and United States) a large
number of participants used the presence or absence of
symptoms to indicate whether their blood pressure was
raised,21 22 27 28 32 37 57-59 65 72 as illustrated by a participant in the
study from Denmark65:
When I got on medication I felt a change for the better
in 14 days . . . the headache lifted and I felt 95 percent
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well . . . and that’s where it’s at. It hasn’t changed
since then. It’s not headache, it’s a heaviness which
makes you constantly aware of the fact that there is
something wrong. It’s like a chunk of lead swimming
around inside the head and I can feel in the teeth and
in my gums and when I’m sitting quietly in a chair I
can feel the pumping pressure
Attitudes to drug taking
Participants in nine studies (Brazil, Netherlands, Thailand,
United Kingdom, and United States) reported taking drugs
regularly according to the prescription.23 28 32 33 40 56 60 64 73A belief
that drugs were essential is illustrated by a participant in one of
the Brazilian studies64:
It is effective if I take it every day, I can’t miss a single
day
A participant in one of the US studies described how she planned
to ensure she never ran out of tablets33:
I have to make sure I do it like two weeks in advance
to make sure I get there . . . I let the medication get to
a certain number of pills and then I’ll call them . . .
get my medication and there won’t be a break in
between me taking it
Intentional non-adherence: link between
hypertension, stress, and symptoms
Deliberately choosing to avoid or reduce treatment (intentional
non-adherence7) was a theme recurring in many of the studies.
People from the Netherlands, the United Kingdom, and the
United States (11 studies) reported that symptoms made them
more likely to take drugs and lack of symptoms less likely to
do so.21 22 27 28 56 58 People fromBrazil, Denmark, the Netherlands,
Thailand, the United Kingdom, and the United States (10
studies) reported they took drugs exclusively only when
symptoms were present.21 22 28 32 37 56 59 58 60 64 65A participant from
the Thai study described how he came to restart treatment after
a period of feeling well60:
At that period, I did not visit the doctor because I did
not have any symptoms. Then I had symptoms again.
I had severe headaches, so I went to a hospital . . .
after I took medication, my headaches were gone. I
recognised that my high blood pressure had not
disappeared
A participant in the Canadian study stopped taking drugs as he
preferred instead to control blood pressure by reducing stress62:
I dropped them. I didn’t last long with them. I said to
myself, I’ll try to fix my pressure myself. . . . I worked
with doctors. They told me that I would end up having
to take them but I didn’t want to. . . . I’m not a big
pill-taker
Studies from theNetherlands, Sweden, and the United Kingdom,
reported that participants perceived that treatment was not
needed at times of reduced stress, with one participant reporting
that he didn’t take drugs in his home country, where he felt
more relaxed.18 22 71 A quote from the Swedish study illustrates
this71:
I use my blood pressure pill after how I feel. So when
I’m relaxed and not under any stress like in summer
when it’s nice weather and vacation, I’ve never taken
any blood pressure pills
Intentional non-adherence: dislike of side effects,
fear of addiction
People widely reported intentionally missing doses (Canada,62
Netherlands,22 Thailand,60 United Kingdom,56 20 and United
States33) or stopping treatment for a time without informing their
doctor (Canada,62Denmark,65 Spain,37Netherlands,22 Thailand,60
United Kingdom,18 20 28 56 and United States31 33 45 63).
Participants from Spain, the United Kingdom, and the United
States experimented with stopping treatment to see how they
felt without it.28 37 45 Participants from Brazil, Canada, Spain,
the United Kingdom, and the United States reported that they
self adjusted their drug dose, often because of a desire to avoid
side effects or a perception that their blood pressure was
controlled.20 32 33 37 56 57 62 A few participants in two studies
(United Kingdom and United States) omitted treatment when
using alcohol or recreational drugs owing to fear of a harmful
interaction.56 57 63
Participants from Canada, Thailand, the United Kingdom, and
the United States (in 10 studies) reported a fear of long term
problems from taking drugs.18 20 33 51 52 56 57 59 60 62 73 These were
described as a “build up” of drugs in the body or developing a
tolerance or addiction to the drugs. A participant from a UK
study described his reluctance to take drugs57:
I prefer to let nature take its course as far as my body
is concerned. I’m not one to introduce anything to it
if I’m feeling alright. If I’m feeling ill I will take any
medication that will make me better or even cure me,
but if I feel better I don’t see why I should take it,
because I don’t want to be addicted to nothing other
than food and water
Other adverse effects were often reported, such as ankle
swelling, lethargy, and urinary frequency. Impotence was
mentioned widely by men as a troublesome side effect of
treatment (Netherlands, Thailand, United Kingdom, and United
States).20 22 31 56 57 59 60 73
Intentional non-adherence: alternative medicines
Participants from six countries (12 studies) reported
supplementing or replacing drugs with a wide range of
traditional and alternative medicines (table 4⇓). Traditional
treatments were widely perceived to be safer and more natural
than drugs.
Non-intentional non-adherence
Participants described various external factors that limited their
ability to adhere to treatment (non-intentional non-adherence7).
Participants commonly forgot to take drugs from time to time
in studies from Canada, South Korea, Spain, the United
Kingdom, and the United States (10 studies in
total).31 34 37 39 45 48 62 63 73 Participants in eight studies (New
Zealand, South Korea, and United States) reported that other
commitments meant that they were too busy to take drugs or to
attend medical appointments.31 34 39 48 49 59 63 74 Participants from
two Brazilian studies and seven of the US studies reported that
hypertension care was too expensive: the costs of drugs, healthy
food, and visiting doctors were all reported as
barriers.32-34 39 40 44 59 63 64 76 Participants in three of the US studies
reported that not having health insurance hindered them from
accessing medical care.32 39 63
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Robustness of findings
The studies were generally of high quality (mean quality score
9.8 out of 11). Sensitivity analyses were done for the key themes
(connecting hypertension with stress, having symptoms, using
symptoms to judge blood pressure levels, taking drugs only
when symptoms were present). These showed that the principal
results were robust when limiting the analysis to the highest
quality studies (excluding those scoring <9 out of 11 for quality),
studies not carried out in an ethnic minority group, and studies
done outside the United States (table 5⇓).
Discussion
In this systematic review on people’s perspectives on
hypertension and drug taking, many participants in the individual
studies perceived stress to be the primary cause and exacerbating
factor of hypertension. They widely described symptoms they
perceived to be caused by hypertension, particularly headache,
palpitations, and dizziness. Contrary to the conclusions of
individual studies, these symptoms were consistent among
different ethnic and geographical groups. Notably, these
symptoms are also commonly reported as being caused by
anxiety in the biomedical literature.77
Participants intentionally adjusted their drug dose, took drugs
sporadically, and stopped altogether, often without consulting
their doctor. Reasons given for reducing treatment included a
perception that blood pressure had improved because of a
reduction in symptoms, that drugs were unnecessary when under
less stress, a dislike of taking drugs, a fear of addiction or
tolerance, and side effects.
Comparison with other research on health
understanding
A systematic review in 2005 included 37 qualitative studies
looking at drug taking in any medical condition (including four
hypertension studies also reported in this review).8 That review
also found that drugs were seen as undesirable and that many
participants feared dependence and tolerance. Participants often
tested new drugs for a time to check for adverse effects and
whether symptoms were reduced. Our review provides
confirmatory evidence from a larger number of studies that these
themes are important in hypertension and adds further themes
important in hypertension specifically, particularly around stress
and symptoms.
Quantitative research provides some evidence that the themes
presented here are widespread. A UK study found that 43% of
people used complementary medicine to treat hypertension.78
Two US studies found that most participants had symptoms
they believed to be caused by hypertension (71-94% in the first
study, 70% in the second study).79 80
Comparison with biomedical model
Stress and symptoms
The nature of the connection between hypertension and stress
has been researched extensively. Acute stress has been shown
to temporarily increase blood pressure levels.81 Evidence from
observational studies has also shown that chronic stress can be
associated with a sustained rise in high blood pressure.82 In the
medical literature, however, stress is considered in the context
of other important risk factors for hypertension, both modifiable
and non-modifiable: age, ethnicity, family history, obesity, a
sedentary lifestyle, and alcohol and salt intake.1 While
participants in our review widely reported avoiding stressful
situations, a meta-analysis of randomised controlled trials of
relaxation interventions for people with hypertension found that
they did not substantially improve blood pressure levels, nor
did the trials find good evidence of an effect on cardiovascular
disease or mortality.83 From themedical perspective, stress plays
a small part in hypertension, whereas a recurring theme in the
studies presented here was that stress was by far the most
important cause.
Likewise, the biomedical literature suggests that symptoms are
more likely to be connected with anxiety and stress than blood
pressure itself. Although people with hypertension in
observational studies have been found to report symptoms, these
studies also found that symptoms did not coincide with periods
of raised blood pressure when measured clinically.84 85 It was
also found that these symptoms were significantly more likely
in anxious people. A larger study in the general population found
the same association with nervousness, but also found no link
with periods of high blood pressure.86
Benefits and adverse effects
Side effects were a widely reported reason for self adjusting or
stopping drugs. Participants in these studies described a range
of adverse effects of treatment, many of which are listed in the
medical literature, including leg swelling, urinary frequency,
fatigue, and impotence.87-89 Other longer term fears about the
drugs, such as the perception of addiction “building up” over
time, or acting as sedatives, are not present in the medical
literature. A fear of addiction is not exclusive to hypertension:
qualitative studies have found that participants with other
chronic medical problems reported identical views.8Conversely,
participants in several studies in this review reported seeing
treatment as essential, stating they would not contemplate
missing even a single day. The responses from some participants
suggest they thought that treatment abolished any risk of
cardiovascular disease.33 The benefit assumed by these
participants is much greater than the small absolute reductions
in risk found in clinical trials.90
Overlap with biomedical model
Rather than being entirely separate, participants’ understandings
of hypertension overlapped with many aspects of the biomedical
model. Aside from the universally strong emphasis placed on
stress, the causes and consequences of hypertension reported
by participants are identical to those in any medical textbook.
The largest included study examined this contradiction in more
depth.24 In this study individual participants often held mutually
contradictory explanations, and the inconsistencies did not
trouble them.
Similarities among cultural, ethnic, and
geographical groups
Previous studies have examined the health beliefs of specific
ethnic groups; in particular, many have been done in
African-American people, to explore cultural factors influencing
low rates of hypertension control.91 The authors of many of the
studies in this review concluded that specific culturally
appropriate education is needed, implying that their findings
were unique in the particular population studied. However, the
principal themes identified here were remarkably similar across
geographical and ethnic groups. Participants in most of the
studies perceived hypertension as a symptomatic illness
associated principally with stress; this was confirmed in the
sensitivity analyses looking at studies that were not restricted
to minority ethnic groups, and in the non-US studies.
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Differences between cultural, ethnic, and
geographical groups
Racismwas often reported by participants fromminority ethnic
groups. In several studies from the United States of African
Americans and one of Filipino-Americans and one study of
people of black Caribbean ethnicity in the United Kingdom, the
stress caused by racismwas reported to exacerbate hypertension.
Migrant populations also perceived that they were more likely
to have low paying jobs and experience greater economic
hardship. African-American participants from two US studies
reported a lack of trust of their white doctors, perceiving
prejudice against them.
A UK study that compared the reports from black Caribbean
and white British participants found that a large number of black
Caribbean participants reported self adjusting and stopping
drugs, whereas all but one white British participant reported
taking drugs regularly. Although a traditional diet was
mentioned as an exacerbating factor for hypertension in many
studies, this did not seem to be unique to any particular group.
A Dutch study found that people of Surinamese, Ghanaian, and
white European ethnicity equally thought that their traditional
diet worsened their blood pressure.22
Implications for clinicians and hypertension
education
The evidence presented here adds weight to the criticism of
educational interventions that assume poor adherence is due to
patients’ failings, either in knowledge or remembering to take
drugs.92 The participants in the studies presented here did not
simply have a knowledge deficit but held alternative
explanations for their hypertension; many deliberately chose to
avoid drugs.
This may explain why educational interventions that simply
inform about the conventional medical view have proved
ineffective.9 To better deal with these problems, clinicians and
educational interventions must acknowledge and incorporate
patients’ concerns and perspectives. Specifically, patients should
be given an honest and accurate representation of the likelihood
of benefit and adverse effects with treatment. The evidence of
safety of long term use of drugs should be discussed, including
that treatment is not thought to “build up” in the body or to
cause a physical dependence. Fears about addiction could be
further tackled by informing patients that they are unlikely to
experience adverse effects if they decide to stop, no matter how
long they have taken the treatment. This is in stark contrast to
existing educational interventions, which emphasise the
importance of continuous tablet taking.9
Rather than denying the possibility of symptoms, patients’
experiences should be acknowledged. Patients could be informed
that people with hypertension often report symptoms but that
they have not been found to be a reliable indication of
fluctuations in blood pressure levels. Patients could be informed
that their risk of cardiovascular disease is increased regardless
of whether they have symptoms, and that treatment can
effectively prevent cardiovascular disease.
Stress should be placed in the context of other modifiable and
non-modifiable risk factors for hypertension and cardiovascular
disease; it should be noted that relieving stress alone is not likely
to normalise blood pressure and that treatment is recommended
at times of high and low stress.
Non-intentional factors, such as forgetting and being busy, were
mentioned by many participants as reasons for not taking drugs,
and there is low quality evidence from randomised controlled
trials that reminder interventions may have an effect.9However,
the qualitative research suggests that reminders alone that
neglect patients’ health understanding are not likely to provide
a highly effective solution.
Finally, we did not find strong evidence that educational
interventions for hypertension need to be tailored to a particular
cultural or ethnic group; the consistency of the results presented
here suggests that it is more important to take account of
common understandings and experiences across the world.
Strengths and weaknesses of the review
This study used a systematic strategy for identifying, reporting,
and synthesising qualitative research. Several features suggest
that the results are robust. Firstly, we identified a large number
of studies, which were largely judged to be of high quality.
Secondly, many of the themes we identified were reported
repeatedly in a large number of papers. These themes did not
vary substantially across different countries. Thirdly, the results
of sensitivity analyses, when we removed the groups of papers
thought possible to cause bias, did not change the conclusions
of the main analysis.
We chose to use the Economic and Social Research Council
guidance on narrative synthesis as it both encourages transparent
reporting and places a strong emphasis on assessing the
robustness of results; the lack of both has been a criticism of
other methods of synthesising qualitative research.93 Although
no formal test of different synthesis methods versus each other
exists,93 the strong evidence of themes found here and the large
degree of overlap between narrative synthesis and other
qualitative synthesis methodologies suggest that other methods
would have produced similar results.
We made a pragmatic decision to include studies from peer
reviewed journals only, to retrieve the highest quality research.
It seems likely that a body of qualitative research also exists in
book chapters, university theses, and conference presentations,
that was not included in this review. Although we used no
language restriction for inclusion of studies and included some
non-English language papers, we would have missed those not
listed on English language databases.
Certain groups in the research were represented
disproportionately: nearly half of the studies looked at an ethnic
minority population and nearly half were done in the United
States. Although this presented a potential source of bias, the
themes in these papers did not differ substantially from those
from other countries and from studies without restriction to an
ethnic group.
Implications for research
This review examined the importance of patients’ health
understanding for one aspect of cardiovascular disease
prevention. Syntheses of the qualitative research on other
cardiovascular risk factors would complement the findings and
could help inform the development of new interventions.
Carrying out a systematic reviewwhen planning new qualitative
research may help to avoid the unintentional examination of
questions that have already been extensively researched. Finally,
when developing future educational interventions, it may be
more rewarding for researchers to consider shared explanations
for hypertension rather than attempting to target a specific ethnic
or cultural group.
Implications for practice
Lay perspectives about hypertension are often different from
the medical viewpoint: worldwide, people widely perceive that
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hypertension is principally a stress related condition with
symptoms and fear addiction or dependence on drugs. These
commonly caused people to reduce or stop treatment. If they
are to be successful at improving adherence, future educational
interventionsmust incorporate and engagewith these widespread
perspectives and experiences rather than simply reiterating the
biomedical view. A greater understanding between doctors and
their patients must play a part in future strategies for reducing
cardiovascular disease.
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Tables
Table 1| Description of included studies
Specific ethnic
group interviewedRecruitment sitePopulationStudy typeStudy (country)
NSSix general practices25 men and women aged 37-70; each prescribed
1-5 hypertension drugs
Focus groupsBane18 (Northern
Ireland)
NSUrban general practice28 men and women (62% women), wide age range
reported as frequency table; 50% prescribed 1
hypertension drug, 11% prescribed ≥3 or more
InterviewsBenson19 20 (UK)
African-SurinameseInner city general practices15 men and women (75% women) aged 35-65; all
prescribed ≥1 hypertension drugs in past year, range
not reported
InterviewsBeune21 (Netherlands)
Ghanaian,
African-Surinamese,
and white European
ethnicity
Inner city general practices46 men and women aged 35-65; all prescribed ≥1
hypertension drugs, range not reported
InterviewsBeune2223 (Netherlands)
Majority whitePrimary care centre for military veterans117 men and women (98% men), all formerly in
armed forces, aged 22-79; drug use not described
InterviewsBlumhagen24 (USA)
African-AmericanCommunity social events and word of
mouth
37 men and women aged 43-88; 89% prescribed ≥1
hypertension drugs
InterviewsBoutain25 (USA)
African-AmericanRural parish church in south Louisiana30men and women, median age 55; 83% prescribed
≥1 hypertension drugs
InterviewsBoutain26 (USA)
African-AmericanGeneral practice60 men and women (92% women) aged 29-84 with
poorly controlled hypertension; prescribed drug not
reported
InterviewsBoutin-Foster27 (USA)
Black Caribbean
from Jamaica,
Guyana, and
Trinidad
Inner city general practice19 men and women aged 40-75; prescribed drug
not reported
InterviewsConnell28 (UK)
NSHypertension register from primary care
clinic
21 people; ages and prescribed drug not reportedInterviewsCosta29 (Brazil)
NSHypertension register from primary care
clinic
25 women; ages and prescribed drug not reportedFocus groupsCosta e Silva30 (Brazil)
Filipino-AmericanFour health maintenance organisation
primary care clinics
27 men and women, ages not reported; all
prescribed ≥1 hypertension drugs
Focus groupsDela Cruz31 (USA)
NSInterviewees were subsample of those
taking part in hypertension clinical trial
30 men and women aged ≥60; prescribed drug not
reported
InterviewsFirmo32 (Brazil)
African-Americaninner-city free primary care clinic20 women aged 35-68; all prescribed ≥1
hypertension drugs
Focus groupsFongwa33 (USA)
African-American12 rural African methodist episcopal
churches
25 women aged 40-74; prescribed drug not reportedFocus groupsFord34 (USA)
OjibweChronic disease register at local health
centre and word of mouth
29 men and women aged 28-79; prescribed drug
not reported
InterviewsGarro35 36 (Canada)
NSPatients of primary care centres, telephone
screened to find non-adherent patients
44 men and women, ages not reported; all
prescribed ≥1 hypertension drugs
Focus groupsGascon37 (Spain)
Moroccan JewishPrimary care clinic22 men and women aged 39-75; prescribed drug
not reported
InterviewsGreenfield38 (Israel)
African-AmericanOutpatient clinic with 21% patients
uninsured, 25% covered by Medicaid
37 men and women aged 25-68, 27 of whom were
prescribed ≥1 hypertension drugs
Focus groupsGreer39 (USA)
African-AmericanOutpatient general medical and
hypertension clinics of large public hospital
60 women aged 45-70; all prescribed ≥1
hypertension drugs
InterviewsHeurtin-Roberts40 41
(USA)
Black Caribbean13 general practices with high ethnic
minority populations in Midlands and north
of England
36 men and women aged 37-82; prescribed drug
not reported
Focus groups and
interviews
Higginbottom42 43 (UK)
African-American
and Latino American
Outpatient clinics in four hospitals in east
and central Harlem
88men and women, 34% aged >65; prescribed drug
not reported, 36% reported to be uncontrolled
Focus groupsHorowitz44 (USA)
African-AmericanEmergency department (free blood
pressure check service), and from
physician’s patient lists
21 men and women aged 65-92 identified by their
physicians as non-adherent to hypertension drugs
InterviewsJohnson45 (USA)
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Table 1 (continued)
Specific ethnic
group interviewedRecruitment sitePopulationStudy typeStudy (country)
NSHalf from rural general practice; half from
hypertension specialist clinic in city
hospital
33 men and women aged 35-83; all with experience
of taking ≥1 hypertension drugs at time of interview
or in past
InterviewsKjellgren46 (Sweden)
NSQualitative interviews of participants in
clinical trial of long term hypertension
educational intervention
21 men and women aged 32-63 engaged in trial of
educational intervention, 2 of whomwere prescribed
≥1 hypertension drugs
InterviewsLahdenpera47 (Finland)
NSPublic health centre taking part in national
hypertension initiative; private medical
practices, and medical practices looking
after employees of various companies
26 men and women, all reported to be
non-compliant, aged from 31 to >65
InterviewsLee48 (South Korea)
African-AmericanThrough word of mouth via respected
professionals and community leaders
40 men and women aged 21-82, all prescribed ≥1
hypertension drugs
Focus groupsLewis49 (USA)
African-AmericanUrban multidisciplinary care centre for
elderly people serving principally low
income, frail elderly people
21 women aged 57-86, each prescribed 1-3
hypertension drugs
InterviewsLewis50 (USA)
NSOne urban primary health care centre21 men and women, ages not reported; all
prescribed ≥1 hypertension drugs
InterviewsLisper51 (Sweden)
African-AmericanPrimary care clinic at large municipal
hospital serving mostly uninsured or
Medicaid insured patients with low
education levels
42 men and women aged 33-63; separate groups
for participants identified as non-adherent and
adherent to drugs
Focus groupsLukoschek52 (USA)
NSPrimary care11 men and women, ages not reported; all
prescribed ≥1 hypertension drugs
InterviewsMachado53 (Brazil)
NSRecruitment site unclearNumber of people and ages unclear; all prescribed
≥1 hypertension drugs
InterviewsMohammadi54 (Iran)
NSFive general practices in East Midlands28 men and women aged 20-78, all prescribed ≥1
hypertension drugs
InterviewsMorecroft55 (UK)
Black Caribbean,
and white British
15 inner city general practices60 men and women aged 35-55; 58 prescribed ≥1
hypertension drugs
InterviewsMorgan56 57 (UK)
African-AmericanPrimary care practice in New York
university hospital
93 men and women, mean age 58, prescribed mean
of 2 hypertension drugs; 60% reported as
uncontrolled
InterviewsOgedegbe58 (USA)
African-AmericanTwo primary care practices in New York,
first with diverse population, second
predominantly serving people with low
income
106 men and women, mean age 56 (SD 13) years,
prescribed mean of 2 hypertension drugs
Interviews (some
via telephone)
Ogedegbe59 (USA)
NSUniversity hospital outpatient clinic16 men and women aged 34-75; 96% prescribed ≥1
hypertension drugs
InterviewsPanpakdee60 (Thailand)
NS2 inner city primary care clinics32 men and women aged 37-81; prescribed
hypertension drug not reported
Interviews
(semistructured,
content analysis)
Peres61 (Brazil)
NSSubsample of participants of larger clinical
trial who identified themselves as
non-adherent
27 men and women recruited from adherence study,
each prescribed 1 hypertension drug
InterviewsProulx62 (Canada)
African-AmericanSubsample of participants of larger clinical
trial
19 men aged 33-49 recruited from hypertension
clinical trial
InterviewsRose63 (USA)
NSThose attending an adult health
programme
21 men and women; ages and prescribed drugs not
reported
InterviewsSadala64 (Brazil)
NSFour general practices17 men and women aged 34-50; prescribed 1-3
hypertension drugs
InterviewsSångren65 (Denmark)
African-AmericanSeveral local churches and local public
health department clinic
41 men and women aged >65; prescribed drug not
reported
InterviewsSchoenberg66 (USA)
NSThose attending an adult health
programme
8 men and women; ages and prescribed drugs not
reported
InterviewsSilva67 (Brazil)
NSGeneral practice in south of England with
nurse led hypertension clinic
49 men and women aged 38-84; 45 of whom were
prescribed ≥1 hypertension drugs
InterviewsSims68 (UK)
NSMonthly hypertension clinic at Ghana
Health Mission
100 men and women; ages reported as categories
from 18 to >75; prescribed drug not reported
InterviewsSpencer69 (Ghana)
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Table 1 (continued)
Specific ethnic
group interviewedRecruitment sitePopulationStudy typeStudy (country)
NSSmall hypertension and diabetes clinic in
suburb of city
33 men and women in focus groups, 11 of whom
were interviewed individually; prescribed drug not
reported
Focus groups and
interviews
Strahl70 (Tanzania)
NSGeneral practice and specialist
hypertension clinic
33 men and women aged 35-83, with experience of
taking ≥1 hypertension drugs at time of interview or
in past; 55% prescribed 1 hypertension drug
InterviewsSvensson71 (Sweden)
2 Maori, rest white
European
Register of previous research participants
from Wellington School of Medicine
19 men and women (79% women) aged 41-67; all
prescribed ≥1 hypertension drugs
Interviewsvan Wissen72 (New
Zealand)
African-AmericanCommunity health centre, Chicago20 women, ages presented as categories from 25
to >75; all prescribed ≥1 hypertension drugs
InterviewsViswanathan73 (USA)
SamoanAuckland general practice20 men and women, 10 reported to have poor
adherence aged 41-81, all prescribed ≥1
hypertension drugs; patients with low adherence
and good adherence selected for interview
InterviewsWai74 (New Zealand)
NS2 general practices11 men and women aged 41-82 with diagnosis of
hypertension in past 6 months; prescribed drugs not
reported
InterviewsWeaver75 (UK)
African-AmericanPatients of Ohio State University primary
care research clinic
26 men and women (77% women) aged 32-71;
prescribed drug not reported
Focus groupsWexler76 (USA)
NS=none specified.
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Table 2| Reported causes of hypertension
Countries, studiesPerceived causes of hypertension
Brazil31 61 64 67;Canada35 62;Denmark65; Ghana69; Israel38; Netherlands21 22 23 (2 studies); South Korea48; Tanzania70; Thailand60;
UK18 57 68; USA24 25 27 31 33 40 49 52 76
Stress
Brazil32 61 64 67; Canada35; Israel38; Netherlands21 22; USA24 31 33 34 41 44 52 76; UK56 68Food
Brazil64 67; Netherlands22; South Korea48; Tanzania70; UK56 68; USA76Being overweight
Canada35; Netherlands21 22; USA27 33 40; Brazil32 67; South Korea48; UK56Family history
Brazil67; Netherlands22;South Korea48; USA31 76Lack of exercise
Brazil67; Canada35; Netherlands22; UK57 68; USA24Alcohol
Brazil32; Israel38; Thailand60; USA24Heat
Canada35; UK56; USA24Smoking
Canada35; Tanzania70Pregnancy
Canada35 Israel38Witchcraft/spirits
Canada35Exposure to cold
USA24Too much water
Canada35Over-exertion
Canada35Hysterectomy
Canada35Diabetes
Canada35Blood transfusion
Canada35Exposure to farm chemicals
Canada35Eye strain
Canada35Nightmares
USA40Thick blood
USA24 40Blood rising
Netherlands23Bad climate
USA27Kidneys
USA27Resistance to blood flow
USA33Heart pumping harder
Israel38Too much blood
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Table 3| Symptoms most widely associated with hypertension
Countries (No of studies)Symptom
Brazil (4), Canada (1), Denmark (1), Ghana (1), Netherlands (2), South Korea (1), Sweden (2), UK (2), USA (8)Headache
Brazil (3), Canada (1), Denmark (1), Ghana (1), Netherlands (1), New Zealand (1), South Korea (1), Sweden (1), Tanzania (1), Thailand
(1), UK (3), USA (9)
Dizziness
Brazil (3), Canada (1), Netherlands (1), Sweden (1), Tanzania (1), USA (3)Palpitations/racing heart
Brazil (1), Canada (1), Netherlands (1), Tanzania (1), UK (1), USA (1)Sweating
Brazil (3), Canada (1), Denmark (1), Ghana (1), Sweden (2), UK (1), USA (2)Tiredness
Brazil (3), South Korea (1), Spain (1), USA (2)Neck pain
Brazil (2), Spain (1), Thailand (1), USA (1)Nausea/vomiting
Brazil (2), Canada (1), UK (1), USA (1)Chest pain
Brazil (1), Canada (1), UK (1), USA (4)Visual changes
Brazil (2), USA (2)Feeling nervous/irritable
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Table 4| Non-drug treatments reported
Alternative treatments reportedCountry, study
Avocado leaf tea, boldo tea, garlic, lemon balm, passion fruit juice, rosemary, sugar water, tea leaf chayote, waterBrazil32 61
Acupuncture, bush-suporo, blanched celery, coconut bark, cucumber, garlic, garlic tea, homeopathy, neem, papaya leaf, perekese, red cotton,
tamarind, prayer
Netherlands21 23
Lemons, nettle teaSpain37
Jorn, hed lin cheu, khin chai, meditation, pha talaiThailand60
Aloe vera, banana leaf, “bitters,” “blood toner,” breadfruit leaf, cerasee, ginseng, green papaya, medina, royal jelly, sorocee teaUK28 43 56 57
Acupuncture, coconut oil, garlic, ginger, guava, guava leaves, herbal teas, home brewed mango leaves, lemons, lime, lemon grass, massage,
noni juice, pito-pito, poltices, prayer
USA31 33 40 52
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Table 5| Examples of sensitivity analyses
Countries, studiesTheme (group excluded)
Stress as cause of hypertension:
Brazil32 61 64 67; Canada62; Denmark65; Ghana69; Tanzania70; Thailand60; USA24Excluding studies in specific ethnic groups
Brazil32 61; Canada35 62; Denmark65; Israel38; Netherlands22 23 (1 study); Thailand60; UK57; USA24 25 27 33 40 49 52 76Excluding lower quality studies*
Hypertension causes symptoms:
Brazil32 61 6467; Denmark65; Ghana69; New Zealand72; South Korea48; Spain37; Sweden46 71; Tanzania70; Thailand60; UK20Excluding studies in specific ethnic groups
Brazil32 61; Canada35; Denmark65; Netherlands22 23 (1 study); New Zealand72; South Korea48; Spain37; Sweden46 71;
Thailand60; UK20 28 56 57 (3 studies); USA27 33 34 40 52 58 63 66
Excluding lower quality studies*
*Quality score <9/11.
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Figure
Flow of studies through review
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